63 96
[25]
Krabbe LM, Lotan Y, Bagrodia A, et al. Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract–is there evidence for discordant biology? J Urol 2014;191:926–31.[26]
Catto JW, Azzouzi AR, Rehman I, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progres- sion in transitional cell carcinoma. J Clin Oncol 2005;23:2903–10.
[27]
Monteiro-Reis S, Leca L, Almeida M, et al. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation. Eur J Cancer 2014;50:226–33.
[28]
Porten S, Siefker-Radtke AO, Xiao L, et al. Neoadjuvant chemother- apy improves survival of patients with upper tract urothelial carcinoma. Cancer 2014;120:1794–9.[29]
Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J. A systematic review and meta-analysis of adjuvant and neoadju- vant chemotherapy for upper tract urothelial carcinoma. Eur Urol 2014;66:529–41.
[30]
Roscigno M, Brausi M, Heidenreich A, et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 2011;60:776–83.E U R O P E A N
U R O L O G Y
F O C U S
1
( 2 0 1 5
)
5 4 – 6 3
63